Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00568126
Recruitment Status : Completed
First Posted : December 5, 2007
Results First Posted : August 26, 2020
Last Update Posted : August 26, 2020
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Center for Complementary and Integrative Health (NCCIH)
A Healthy Alternative, LLC
Information provided by (Responsible Party):
David Mischoulon, MD, PhD, Massachusetts General Hospital

Brief Summary:
The purpose of this study is to find out whether Maca Root is effective for treating sexual dysfunction in females that is caused by antidepressant drugs. An additional aim of the study is to document the safety and tolerability of maca root, as well as any potential side effects that it causes.

Condition or disease Intervention/treatment Phase
Antidepressant Induced Sexual Dysfunction Drug: Maca Root Drug: Placebo Phase 3

Detailed Description:
This is a 12-week, double-blind, placebo-controlled trial comparing maca root (3.0 g/day) versus an inactive placebo in female outpatients with SSRI/SNRI-induced sexual dysfunction whose depression had remitted with SSRI treatment. Outcome measures include improvement in sexual functioning as per the Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects were randomized in a double blind manner to maca root or placebo. Improvement in sexual functioning was compared between the two treatment groups.
Masking: Double (Participant, Investigator)
Masking Description: Study subjects and investigator clinicians were blinded to the treatment assignment.
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo Controlled Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females
Actual Study Start Date : December 27, 2007
Actual Primary Completion Date : October 5, 2010
Actual Study Completion Date : October 5, 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antidepressants

Arm Intervention/treatment
Experimental: Maca Root
Subjects in this arm will be given 3g/day of maca root for 12 weeks
Drug: Maca Root
3g/day of Maca Root for 12 weeks.
Other Name: Lepidium

Placebo Comparator: Placebo
Subjects in this arm will receive inactive placebo for 12 weeks.
Drug: Placebo
Placebo provided by research pharmacy daily for 12 weeks.
Other Name: Inactive placebo




Primary Outcome Measures :
  1. Proportion of Participants in Remission Based on Arizona Sexual Experience Scale (ASEX) Score of 10 or Less After 12 Weeks of Treatment. [ Time Frame: 12 weeks ]
    Arizona Sexual Experience Scale (ASEX) consists of five items rating sexual drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm.The range of total score is 5-30 with the higher scores indicating greater sexual dysfunction. A total final score of 10 or less is considered to indicate remission of sexual dysfunction.

  2. Proportion of Participants in Remission Based on Massachusetts General Hospital Sexual Functioning Questionnaire (MGH-SFQ) Score of 12 or Less After 12 Weeks of Treatment. [ Time Frame: 12 weeks ]
    Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) is composed of five items evaluating libido, sexual arousal or excitement, ability to achieve orgasm, ability to achieve and maintain an erection (for men only) and overall sexual satisfaction. Items are rated on a scale of 1 to 6 with a rating of 1 indicating greater than normal functioning and a rating of 6 indicating totally absent functioning. A total final score of 12 or less is considered to indicate remission of sexual dysfunction.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is female, age 18 to 80 years
  • Subject has been taking an SSRI, venlafaxine, or tri/heterocyclic antidepressant for the treatment of depression for at least 8 weeks; and is currently on a stable dose of the antidepressant for at least 4 weeks
  • Subject is currently euthymic (HAM-D < 10) and is without significant anxiety symptoms (HAM-A < 10)
  • Subject must have had no sexual dysfunction prior to taking antidepressant and there must be a clear temporal relationship between the sexual dysfunction and the antidepressant treatment
  • Subject must have been consistently experiencing at least one of the following criteria for at least 4 weeks, with distress or disability:

    • Inability to have an orgasm, according to patient opinion
    • Clinically significant orgasm delay with masturbation or intercourse
    • Inability to attain or maintain until completion of sexual activity an adequate lubrication swelling response of sexual excitement
    • Decreased libido according to patient opinion
  • Subject must be having or had been having some form of regular sexual activity (masturbation, oral sex, intercourse) at least twice monthly prior to the antidepressant treatment and are willing to continue efforts at sexual activity at least once weekly for the duration of the study
  • Subject must be in good general physical health
  • Subject must be able to understand and communicate in English
  • Subject must have given informed consent to participate in the study

Exclusion Criteria:

  • Primary or prior diagnosis of a sexual disorder (other than the side effect of the bipolar medication or symptom of the bipolar disorder)
  • Sexual dysfunction secondary to general underlying medical condition
  • Penile, vaginal, clitoral or other sexual organ anatomical deformities
  • Any uncontrolled psychiatric disorder
  • Alcohol or substance abuse or dependence within the past six months
  • Recent major relationship changes, disruption, or turmoil ongoing or anticipated which are unrelated to her sexual dysfunction
  • Hamilton Depression and/or Anxiety Scale score (either) > 10
  • Blood pressure outside the range of 90/50 - 170/100
  • Known hyperprolactinemia
  • Use of investigational drugs within previous 3 months or during study
  • Current use of other drugs for antidepressant induced sexual dysfunction or other therapies or medications to treat sexual dysfunction
  • Current use of nefazodone
  • Hormone replacement therapy, unless patient has been on stable dose of hormone therapy for at least 3 mo prior to the antidepressant treatment and had no sexual dysfunction while on the same hormone therapy regimen, and there is no change in the HRT during the study
  • Pregnancy, lactating, or planning to become pregnant during the study
  • Child bearing potential subjects unwilling and/or not prepared and/or who are judged unreliable to use an acceptable and verifiable form of contraception during the study
  • Any clinically significant abnormality on the screening physical examination
  • History of hormonal cancers
  • Any medical or psychological condition or social circumstances that would impair subject's ability to participate reliably in the study, or that may increase the risk to subjects or others as a result of participating in this study
  • Dyspareunia secondary to an inflammatory or anatomical condition
  • Prior use of maca for at least two weeks
  • Infection of the urogenital tract that may make sexual activity painful or difficult
  • Subjects whose sexual partners are suffering from and/or receiving treatment for sexual dysfunction
  • Receiving psychosexual or other therapy for sexual dysfunction and not willing to discontinue that treatment at screening
  • Subjects who do not understand and communicate in English
  • Subjects for whom sexual activity is inadvisable
  • Subjects whose sexual dysfunction is considered to be situational
  • Subjects not attempting some form of regular sexual activity at least twice monthly and at least once weekly during study visit intervals for duration of entire study
  • Changes in antidepressant agent and/or dose of medication within the last 4 weeks before baseline visit
  • Participants on medications with a narrow therapeutic window or low therapeutic index for which small variations may be harmful given the lack of systematic experience with drug-supplement interactions (i.e. - cyclosporine, digoxin, warfarin, and antiretrovirals)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00568126


Locations
Layout table for location information
United States, Massachusetts
Depression Clinical and Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Institutes of Health (NIH)
National Center for Complementary and Integrative Health (NCCIH)
A Healthy Alternative, LLC
Investigators
Layout table for investigator information
Principal Investigator: Christina Dording, MD Massachusetts General Hospital
Study Director: David Mischoulon, MD, PhD Massachusetts General Hospital
Publications of Results:
Layout table for additonal information
Responsible Party: David Mischoulon, MD, PhD, Physician, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00568126    
Other Study ID Numbers: 2007P001090
R21AT004385 ( U.S. NIH Grant/Contract )
First Posted: December 5, 2007    Key Record Dates
Results First Posted: August 26, 2020
Last Update Posted: August 26, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No current plan for this. In the event that other researchers inquire about using our data (e.g. in a meta-analysis), we will evaluate how to proceed.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by David Mischoulon, MD, PhD, Massachusetts General Hospital:
Antidepressant Induced Sexual Dysfunction
Depression
Sexual Dysfunction